CANOS ONCOTRACK · DOG CANCER MONITORING TRIAL
After treatment, the question changes.
An exploratory blood-test program for dogs diagnosed with cancer. Canos OncoTrack studies cell-free DNA changes during treatment and follow-up, alongside your veterinary team’s care.
Is treatment working?
Minimal residual disease is the cancer left behind after treatment.
Undetectable by standard imaging or routine labs, residual cancer cells can quietly persist, remaining hidden until the disease progresses.
The trial studies whether changes in these molecular signals can support clinical evaluation alongside existing follow-up tests.
FOR DOGS ALREADY DIAGNOSED
CanosOncoTrack
Continuous data. Clear direction.
By comparing blood samples over time, the OncoTrack trial studies whether molecular changes can help veterinarians assess treatment and follow-up.
01
Set the baseline
One blood draw at diagnosis maps your dog’s unique molecular baseline.
02
Track treatment
Follow-up samples during therapy are measured directly against the starting point.
03
Guard remission
Follow molecular changes through remission alongside scheduled veterinary follow-up.
THE REPORT
A returning signal is an alert, not an instant diagnosis.
An illustrative lymphoma MRD report: a diagnostic baseline, three negative follow-up visits, and a returning signal at week 20.
View sample reportDownload a copyCANINE cfDNA MRD MONITORING · PATIENT C-014 · LYMPHOMA
ILLUSTRATIVE
T4 · 7 Sep 2026
Signal detected
Estimated tumour fraction 7.6%
A cancer-associated signal returns, concordant with the known lymphoma. Warrants clinical review; it does not alone establish relapse.
90.6%
Sensitivity
95.1%
Specificity
87.3%
Negative predictive value
896
Plasma sequencing runs
Our 22 September 2026 preprint (version 1) includes 341 dogs and 896 plasma sequencing runs across four studies. Sensitivity, specificity and predictive value describe nested cross-validation in the diagnostic subset, not validated performance for detecting relapse. The preprint has not been peer reviewed; prospective validation is still needed. Patient results shown here are illustrative. Read the research and methods.
Read in clinical context.
A negative result is not an all-clear
Cancer can be present below the level a blood sample can detect, particularly after treatment.
A returning signal is a prompt, not a diagnosis
It warrants review alongside examination, laboratory findings and imaging before treatment changes.
Timing matters
Results are read against treatment dates, the diagnostic baseline and previous visits.
Canos Guardian, our early detection product, is in development and is not yet available. Guardian — coming soon
Pet parent guides
Make sense of monitoring.
Understanding blood tests
Can blood tests detect cancer in dogs?
Understand routine bloodwork, liquid biopsy and the questions to ask before choosing a cancer-related test for your dog.
Read guideDuring treatment and beyond
How is cancer treatment response monitored in dogs?
A plain-language guide to follow-up care, remission and how cell-free DNA research fits alongside your dog's veterinary care.
Read guide